Work

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Year: 2020

Type: article

Abstract: Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Source: Antiviral Research

DOI: 10.1016/j.antiviral.2020.104787

Authors: Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff

Institutions: The Royal Melbourne Hospital, Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute, Monash University

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,950